Literature DB >> 28668202

Home infusion: Safe, clinically effective, patient preferred, and cost saving.

Jennifer M Polinski1, Mary K Kowal2, Michael Gagnon2, Troyen A Brennan2, William H Shrank2.   

Abstract

BACKGROUND: As the U.S. healthcare payment system shifts from volume to value, identifying care approaches that improve outcomes while lowering costs are essential. We sought to understand the utility of home infusion versus medical-setting infusion as a mechanism to affect the three-part aim: better care, better health outcomes, and lower costs. STUDY
DESIGN: Systematic review.
METHODS: We searched MEDLINE, EMBASE, and Science Citation Index for articles related to the safety, clinical effectiveness, quality of life and satisfaction, and/or costs of home infusion as compared with infusion in an outpatient medical facility or hospital.
RESULTS: Of 253 potentially relevant articles, 13 met all inclusion criteria. Study design, disease state, and outcomes varied considerably. As compared to medical setting infusion patients, home infusion patients were no more likely to experience adverse drug events or side effects (all p>0.05). Clinical outcomes were as good or better, e.g., for patients with hemophilia, a 40% (0.50-0.70) reduced likelihood of hospitalization for bleeding complications. Patients overwhelmingly preferred home infusion, reporting significantly better physical and mental well being and less disruption of family and personal responsibilities. Home infusion costs were significantly lower than medical setting infusion costs, with savings between $1928 and $2974 per treatment course.
CONCLUSIONS: Home infusion care can provide safe, clinically effective care improve patients' quality of life and reduce healthcare costs. As the overhaul of the healthcare payment system gains momentum, the home infusion care delivery model offers strong promise as one in a set of approaches that can improve care and lower costs.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2016        PMID: 28668202     DOI: 10.1016/j.hjdsi.2016.04.004

Source DB:  PubMed          Journal:  Healthc (Amst)        ISSN: 2213-0764


  11 in total

1.  Alternate Settings for Infusions in Inflammatory Bowel Disease Patients: Homing in on Optimal Care.

Authors:  Sasan Mosadeghi; Sasha Taleban
Journal:  Dig Dis Sci       Date:  2019-03       Impact factor: 3.199

Review 2.  Impacts on health outcomes and on resources utilization for anticancer drugs injection at home, a complex intervention: a systematic review.

Authors:  Bénédicte Mittaine-Marzac; Emmanuel Bagaragaza; Joël Ankri; Philippe Aegerter; Matthieu De Stampa
Journal:  Support Care Cancer       Date:  2021-03-25       Impact factor: 3.603

3.  Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.

Authors:  Di Sun; Jennifer R Heimall; Matthew J Greenhawt; Nancy J Bunin; Marcus S Shaker; Neil Romberg
Journal:  JAMA Pediatr       Date:  2022-02-01       Impact factor: 16.193

4.  Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis.

Authors:  Jeffrey T Guptill; M Chris Runken; Michael Eaddy; Orsolya Lunacsek; Rupali M Fuldeore
Journal:  Am Health Drug Benefits       Date:  2019-05

5.  Impacts on health outcomes and on resource utilisation of home-based parenteral chemotherapy administration: a systematic review protocol.

Authors:  Benedicte Mittaine-Marzac; Matthieu De Stampa; Emmanuel Bagaragaza; Joël Ankri; Philippe Aegerter
Journal:  BMJ Open       Date:  2018-05-09       Impact factor: 2.692

6.  Developing a Model of Care for Home Infusions of Natalizumab for People With Multiple Sclerosis.

Authors:  Timothy J Schultz; Anne Thomas; Paul Georgiou; Lynette Cusack; Mahasen Juaton; Lorraine Simon; Kerisha Naidoo; Kevin Webb; Jonathan Karnon; Janakan Ravindran
Journal:  J Infus Nurs       Date:  2019 Nov/Dec

7.  COVID-19 outbreak: An experience to reappraise the role of hospital at home in the anti-cancer drug injection.

Authors:  Bénédicte Mittaine-Marzac; Arsene Zogo; Jean-Christophe Crusson; Valerie Cheneau; Marie-Claire Pinel; Marie-Laure Brandely-Piat; Fatma Amrani; Laurent Havard; Elisabeth Balladur; Taina Louissaint; Laurence Nivet; Joel Ankri; Philippe Aegerter; Matthieu De Stampa
Journal:  Cancer Med       Date:  2021-03-05       Impact factor: 4.452

Review 8.  Clinic- and Hospital-Based Home Care, Outpatient Parenteral Antimicrobial Therapy (OPAT) and the Evolving Clinical Responsibilities of the Pharmacist.

Authors:  Toni Docherty; Jennifer J Schneider; Joyce Cooper
Journal:  Pharmacy (Basel)       Date:  2020-12-07

9.  Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders.

Authors:  Louise Rath; Maria Pia Campagna; Jim Stankovich; Julian Ellis; Vilija Jokubaitis; Denise McCarthy; Cassie Nesbitt; Wei Zhen Yeh; Michael Zhong; Robb Wesselingh; Mastura Monif; Janene Richards; Viet Bui Minh; Olga Skibina; Helmut Butzkueven; Anneke van der Walt
Journal:  Int J MS Care       Date:  2020-12-31

10.  Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial.

Authors:  Timothy J Schultz; Anne Thomas; Paul Georgiou; Mahasen S Juaton; Lynette Cusack; Lorraine Simon; Kerisha Naidoo; Kevin Webb; Jonathan Karnon; Janakan Ravindran
Journal:  Ann Clin Transl Neurol       Date:  2021-07-21       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.